Eastwood Bio Medical Canada Stock Short Ratio
| EBM Stock | CAD 0.40 0.05 14.29% |
Eastwood Bio Medical Canada fundamentals help investors to digest information that contributes to Eastwood Bio's financial success or failures. It also enables traders to predict the movement of Eastwood Stock. The fundamental analysis module provides a way to measure Eastwood Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eastwood Bio stock.
Eastwood | Short Ratio |
Eastwood Bio Medical Canada Company Short Ratio Analysis
Eastwood Bio's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Eastwood Bio Short Ratio | 0.16 X |
Most of Eastwood Bio's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eastwood Bio Medical Canada is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eastwood Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Eastwood Bio is extremely important. It helps to project a fair market value of Eastwood Stock properly, considering its historical fundamentals such as Short Ratio. Since Eastwood Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eastwood Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eastwood Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Eastwood Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Eastwood Bio Medical Canada has a Short Ratio of 0.16 times. This is 95.9% lower than that of the Consumer Staples Distribution & Retail sector and 97.84% lower than that of the Consumer Staples industry. The short ratio for all Canada stocks is 96.0% higher than that of the company.
Eastwood Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eastwood Bio's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eastwood Bio could also be used in its relative valuation, which is a method of valuing Eastwood Bio by comparing valuation metrics of similar companies.Eastwood Bio is currently under evaluation in short ratio category among its peers.
Eastwood Fundamentals
| Return On Equity | -7.47 | ||||
| Return On Asset | -0.62 | ||||
| Profit Margin | (0.65) % | ||||
| Operating Margin | (0.63) % | ||||
| Current Valuation | 27.63 M | ||||
| Shares Outstanding | 68.89 M | ||||
| Shares Owned By Insiders | 69.55 % | ||||
| Number Of Shares Shorted | 496 | ||||
| Price To Earning | (11.43) X | ||||
| Price To Book | 2,943 X | ||||
| Price To Sales | 39.25 X | ||||
| Revenue | 702.08 K | ||||
| Gross Profit | 454.39 K | ||||
| EBITDA | (333.01 K) | ||||
| Net Income | (455.87 K) | ||||
| Cash And Equivalents | 708.26 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 79.61 K | ||||
| Current Ratio | 3.42 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (15.22 K) | ||||
| Short Ratio | 0.16 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | -0.044 | ||||
| Market Capitalization | 27.55 M | ||||
| Total Asset | 274.29 K | ||||
| Retained Earnings | (5.99 M) | ||||
| Working Capital | (1.53 M) | ||||
| Net Asset | 274.29 K |
About Eastwood Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eastwood Bio Medical Canada's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eastwood Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eastwood Bio Medical Canada based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eastwood Stock Analysis
When running Eastwood Bio's price analysis, check to measure Eastwood Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eastwood Bio is operating at the current time. Most of Eastwood Bio's value examination focuses on studying past and present price action to predict the probability of Eastwood Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eastwood Bio's price. Additionally, you may evaluate how the addition of Eastwood Bio to your portfolios can decrease your overall portfolio volatility.